Real-time monitoring and treatment evaluation of MR guided focal ultrasound-mediated non-thermal ablation of brain tumors

磁共振引导聚焦超声介导脑肿瘤非热消融的实时监测和治疗评估

基本信息

  • 批准号:
    10511064
  • 负责人:
  • 金额:
    $ 22.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

There is a clear and urgent unmet clinical need for non-invasive, non-ionizing and non-chemo-toxic treatment options for patients with brain tumors. The long-term goal of this proposal is to develop non- thermal ablation (NTA) using phase shift microbubble-aided Magnetic Resonance guided Focused Ultrasound (MRgFUS) into a new non-invasive treatment option that will provide brain cancer patients with increased survival rates and decreased side effects. The overall objective of this application is to (i) develop novel Magnetic Resonance Imaging (MRI) based methods for real-time monitoring and guidance of the non- thermal ablation process; and (ii) adapt a recently developed and validated voxel-wise in vivo MRI to histopathology registration pipeline to brains, and use it to develop and verify imaging biomarkers which can acutely predict long-term tissue non-viability. The rationale for this project is that a means for non-invasive real-time monitoring which directly image the effect of the treatment on the tissue of interest, together with a thorough understanding of non-thermally induced lesion progression and prediction of long-term tissue nonviability are necessary to facilitate safe and timely translation of non-thermal MRgFUS ablation of brain tumors to large animal models and ultimately to the clinic. We will achieve this in two specific aims; 1) Develop innovative MRI-based approaches for direct real-time monitoring of tissue of interest during non- thermal ablation, and evaluate them based on real-time applicability and sensitivity to acutely detect lesion formation in a rat brain tumor model; 2) Adapt an MRI to histopathology registration pipeline and use it to gain understanding about lesion progression and to develop imaging biomarkers for acute prediction of long-term tissue non-viability. The research proposed in this application is innovative, in the applicant’s opinion, because it will develop sensitive approaches for real-time monitoring of the lesion progression of FUS non-thermal ablation, and will use a MRI-to-histology registration pipeline to develop understanding about lesion progression and develop imaging biomarkers to predict tissue nonviability. Ultimately, this novel non-invasive treatment modality has the potential to provide the tens of thousands of patients diagnosed with brain tumors each year with a safe an efficient treatment option.
对于非侵入性、非电离和非化疗毒性的药物, 脑肿瘤患者的治疗选择。该提案的长期目标是发展非 使用相移微泡辅助磁共振引导的聚焦热消融(NTA) 超声波(MRgFUS)成为一种新的非侵入性治疗选择,将为脑癌患者提供 提高存活率和减少副作用。本申请的总体目标是(i)开发 新的磁共振成像(MRI)为基础的方法,实时监测和指导的非- 热消融过程;以及(ii)调整最近开发和验证的体素方式体内MRI, 组织病理学登记管道,并使用它来开发和验证成像生物标志物, 准确预测组织的长期无活力。该项目的基本原理是, 实时监测,其直接对治疗对感兴趣组织的影响进行成像, 全面了解非热诱导损伤进展和预测长期组织损伤 非存活性是必要的,以促进安全和及时的非热MRgFUS脑消融 将肿瘤转化为大型动物模型并最终用于临床。我们将通过两个具体目标实现这一目标:1) 开发基于MRI的创新方法,用于在非手术期间直接实时监测感兴趣组织。 热消融,并根据实时适用性和灵敏度对它们进行评价,以快速检测病变 2)使MRI适应于组织病理学配准管道,并将其用于 了解病变进展并开发用于急性预测的成像生物标志物 长期组织无活力。本申请中提出的研究是创新的,在申请人的 意见,因为它将开发敏感的方法,实时监测病变进展, FUS非热消融,并将使用MRI到组织学配准管道来加深理解 了解病变进展,并开发成像生物标志物来预测组织的无活力。最终,这部小说 非侵入性治疗方式有可能为成千上万的患者提供诊断 每年都有大量的脑肿瘤患者,有一种安全有效的治疗方案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Henrik Carl Axel Odeen其他文献

Henrik Carl Axel Odeen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Henrik Carl Axel Odeen', 18)}}的其他基金

Real-time monitoring and treatment evaluation of MR guided focal ultrasound-mediated non-thermal ablation of brain tumors
磁共振引导聚焦超声介导脑肿瘤非热消融的实时监测和治疗评估
  • 批准号:
    10659248
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
Feasibility of transcranial histotripsy for pediatric neuro-oncology applications using a hemispherical transducer
使用半球形换能器进行经颅组织解剖用于儿科神经肿瘤学应用的可行性
  • 批准号:
    10570948
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
Feasibility of transcranial histotripsy for pediatric neuro-oncology applications using a hemispherical transducer
使用半球形换能器进行经颅组织解剖用于儿科神经肿瘤学应用的可行性
  • 批准号:
    10433621
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
Advanced Treatment Endpoint Assessment in MR-guided Focused Ultrasound
MR 引导聚焦超声的高级治疗终点评估
  • 批准号:
    10115726
  • 财政年份:
    2020
  • 资助金额:
    $ 22.01万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了